Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
TheFly reported on December 2, 2025, that Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 11,038,834 | $267,912,511 | +25% | 1.59% |
| 2. | Farallon Capital Thomas Steyer | 10,063,111 | $244,231,704 | +1% | 1% |
| 3. | Kynam Capital Derrick Tang | 2,517,647 | $61,103,293 | +5% | 4.55% |
| 4. | Casdin Capital Eli Casdin | 1,600,000 | $38,832,000 | +11% | 3.24% |
| 5. | Contrarius Investment Management Stephen Mildenhall | 1,533,269 | $37,212,439 | 1.68% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.10 | 6,294 | $170,567.40 | 73,706 | 2025-12-31 | Filing | |
| $27.10 | 1,254 | $33,983.40 | 115,667 | 2025-12-31 | Filing | |
| $26.68 | 459 | $12,246.12 | 14 | 2025-10-27 | Filing | |
| $24.53 | 467 | $11,455.51 | 44,045 | 2025-10-01 | Filing | |
| $24.53 | 373 | $9,149.69 | 116,921 | 2025-10-01 | Filing |
Institutional Investors' Holdings
News See All
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here.
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy
On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam Therapeutics (NASDAQ:BEAM).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14, Beam Therapeutics Inc.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results
The revised target reflected the company’s robust performance in the third quarter of 2025. The investment firm pointed toward the first patient dosing in Beam Therapeutics Inc.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
Hedge Fund Resource Center Billionaire Hedge Funds
